Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.84 |
| ▸ | CHAT | P28329 | 2/20 | 0.81 |
| ▸ | EP300 | Q09472 | 3/20 | 0.79 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.79 |
| ▸ | AURKA | O14965 | 2/20 | 0.79 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.79 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26677033 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL30046331 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL26677030 | 0.98 | NAA50 (0.81) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL3194348 | 0.97 | NAA50 (0.83) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL27596832 | 0.96 | NAA50 (0.82) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL19009003 | 0.96 | NAA50 (0.81) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL4436576 | 0.96 | NAA50 (0.81) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL16974407 | 0.96 | NAA50 (0.81) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL19009010 | 0.96 | NAA50 (0.81) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL4587701 | 0.96 | NAA50 (0.81) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028651-A1 | METHOD OF PRODUCING & PROCESSING DIAMINES | AGAIN BIO APS (DK) | 2026-01-29 | — | — | US | disclosed |
| US-20250388910-A1 | METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL | AGAIN BIO APS (DK) | 2025-12-25 | — | — | US | disclosed |
| US-12503711-B2 | Method of producing and processing diamines to a diamine free base using a carbonate intermediate and an engineered microorganism | GENOMATICA, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12398396-B2 | Methods for enhancing microbial production of specific length fatty alcohols in the presence of methanol | GENOMATICA, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-3074504-B1 | METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL | GENOMATICA INC (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240182935-A1 | METHOD OF PRODUCING & PROCESSING DIAMINES | AGAIN BIO APS (DK) | 2024-06-06 | — | — | US | disclosed |
| US-11834690-B2 | Microorganisms and methods for the biosynthesis of adipate, hexamethylenediamine and 6-aminocaproic acid | GENOMATICA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230383319-A1 | ITERATIVE PLATFORM FOR THE SYNTHESIS OF ALPHA FUNCTIONALIZED PRODUCTS | Gonzalez, Ramon (US) | 2023-11-30 | — | — | US | disclosed |
| EP-4273255-A2 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF HEXAMETHYLENEDIAMINE | Genomatica, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11702682-B2 | Method of producing and processing diamines to a diamine free base using a carbonate intermediate and an engineered microorganism | GENOMATICA, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20120329111-A1 | Microorganisms for Producing Cyclohexanone and Methods Related Thereto | GENOMATICA, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120282661-A1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID | GENOMATICA, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120156740-A1 | MICROORGANISMS AND METHODS FOR THE PRODUCTION OF 1,4-CYCLOHEXANEDIMETHANOL | GENOMATICA, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082978-A1 | MICROORGANISMS AND METHODS FOR THE PRODUCTION OF 1.4- CYCLOHEXANEDIMETHANOL | GENOMATICA, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| EP-2429587-A1 | ORGANISMS FOR THE PRODUCTION OF CYCLOHEXANONE | Genomatica, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2427544-A1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID | Genomatica, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20110014668-A1 | ORGANISMS FOR THE PRODUCTION OF CYCLOHEXANONE | GENOMATICA, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20100317069-A1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID | AGAIN BIO APS (DK) | 2010-12-16 | — | — | US | disclosed |
| WO-2010132845-A1 | ORGANISMS FOR THE PRODUCTION OF CYCLOHEXANONE | GENOMATICA, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010129936-A1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID | GENOMATICA, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388910-A1 | METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL | ADH5, ADH1C, ADH1A | NAA50 426/4885CHAT 1999/4885EP300 1466/4885 |
| US-20260028651-A1 | METHOD OF PRODUCING & PROCESSING DIAMINES | DDC, DAO, ODC1 | NAA50 69/4885CHAT 77/4885EP300 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.